Business Context and Reporting Period
This Form 8-K was filed by Zafgen, Inc. on November 9, 2018. The filing reports the entry into a material definitive agreement regarding an equity offering program. Note: The request metadata references "Larimar Therapeutics, Inc.", but the filing text explicitly identifies the registrant as Zafgen, Inc.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial metric disclosed is the authorization of an equity offering program with the following parameters:
- Aggregate Offering Price: Up to $50,000,000.
- Commission Rate: 3.0% of gross sales proceeds paid to the sales agent.
- Securities Type: Common Stock, par value $0.001 per share.
Material Changes
On November 9, 2018, Zafgen, Inc. entered into a Sales Agreement with Cowen and Company, LLC to establish an "at-the-market" (ATM) offering program. This agreement allows the company to sell shares of its common stock through Cowen as a sales agent from time to time at its sole discretion. The issuance is made pursuant to an effective registration statement on Form S-3 (No. 333-219834).
Guidance, Outlook, and Risks
Management Commentary and Terms:
- The company is not obligated to make any sales under the agreement.
- Sales will be conducted based on instructions from the company, including price, time, or size limits.
- Either the company or Cowen may suspend or terminate the offering upon notice.
- Cowen will act on a "commercially reasonable efforts" basis.
Risks and Contingencies:
- The filing explicitly states it does not constitute an offer to sell securities in any state where such an offer would be unlawful prior to registration.
- The description of the agreement is qualified by reference to the full text of the Sales Agreement filed as Exhibit 1.1.
Investor Verification Checklist
- Verify the current share price and trading volume to assess the potential dilution impact of a $50 million ATM program.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination clauses and pricing parameters.
- Confirm the company's current cash position and burn rate to understand the necessity of this capital raise.
- Check subsequent filings to determine if any shares have actually been sold under this program and the total commissions paid.